AML

Phase 3 AGILE results show that ivosidenib plus azacitidine has clinical activity in IDH1-mutant acute myeloid leukemia.

The FDA has granted approval for ivosidenib tablets as treatment for patients with previously untreated IDH1-mutated acute myeloid leukemia.

Melhem Solh, MD, discussed how the post transplantation outcomes for patients with MDS and AML with the TP53 gene mutation have changed to what it is today.

A partial clinical hold has been placed by the FDA on a phase 1 trial examining the use of FHD-286 as treatment for patients with relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome.

In an interview with Targeted Oncology™, Siddhartha Mukherjee, MD, examined the current treatment landscape for acute myeloid leukemia and therapies on the horizon.

Interim results of the ADVANCE II study of DCP-001 revealed durable measurable residual disease responses in patients with acute myeloid leukemia.

Having an antibiotic de-escalation guideline did not affect the rate of bacterial infection after antibiotic de-escalation, all cause-mortality, or hospital length of stay in patients with acute myeloid leukemia and febrile neutropenia who were clinically stable and afebrile.

The FDA has granted a fast track designation to HM43239 for the treatment of patients with relapsed or refractory acute myeloid leukemia whose tumors harbor a FLT3 mutation.

Andrew Wei, MBBS, PhD, discusses outcomes related to long-term survival in the QUAZAR AML-001 trial of oral azacitidine in patients with acute myeloid leukemia.

The FDA has granted orphan drug designation to AB001 for the treatment of patients with pancreatic cancer and acute myeloid leukemia.

The combination of ivosidenib and azacitidine revealed a manageable safety profile and quality of life profile in patients with IDH1-mutant acute myeloid leukemia in the phase 3 AGILE study.

JSP191 combined with fludarabine, and low-dose total body radiation demonstrated facilitation of full donor myeloid chimerism, clearing of minimal residual disease, and a well-tolerated safety profile in older patients with myelodysplastic syndrome/acute myeloid leukemia receiving non-myeloablative allogenic hematopoietic cell transplantation.

The FDA has granted fast track designation to CFI-400945 which has shown encouraging signs of monotherapy activity in patients with acute myeloid leukemia with adverse cytogenetics.

Magrolimab clinical trials including patients with myelodysplastic syndrome and acute myeloid leukemia may continue now that the FDA has lifted a partial clinical hold.

Rajneesh Nath, MD, discusses what is in store regarding treatment for elderly patients with relapsed/refractory acute myeloid leukemia.

The FDA has granted fast track designation to PRGN-3006 for the treatment of patients with relapsed or refractory cute myeloid leukemia .

The phase 1/2 TakeAim Leukemia study exploring emavusertib in patients with acute myeloid leukemia and myelodysplastic syndrome has been halted by the FDA pending more safety and efficacy data.

Orphan drug designation has been granted to TCB-002 for use as a potential therapeutic option in patients with relapsed/refractory acute myeloid leukemia.

Andrew Wei, MBBS, discusses characteristics associated with long-term survival in the QUAZAR AML-001 trial of oral azacitidine in patients with acute myeloid leukemia.

The FDA has granted priority review to ivosidenib tablets as a potential treatment for patients with previously untreated IDH1-mutated acute myeloid leukemia.

In a presentation Eytan M. Stein, MD, reported on single agent inhibitors followed by methods to overcome resistance using combination therapy.

In acute myeloid leukemia, ongoing clinical trials are exploring the potential of this checkpoint alone or as part of a dual immunotherapy regimen.

IO-202 for the treatment of patients with relapsed or refractory acute myeloid leukemia is a strategy under investigation in a phase 1, multicenter, open-label, dose-escalation and expansion study.

With a partial clinical hold placed by the FDA, all studies of magrolimab plus azacitidine must halt screening and enrollment.

The KOMET-001 study may resume after the FDA lifted the partial clinical hold for safety.